Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Praxis Precision Medicines, Inc. (NASDAQ: PRAX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Praxis is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, and its filings offer detailed insight into the development and financing of its precision neuroscience portfolio.
Through Forms 8-K, Praxis reports material events such as topline clinical results, regulatory interactions and capital markets transactions. Recent 8-K filings describe positive Phase 3 Essential3 data for ulixacaltamide in essential tremor, EMBOLD study outcomes for relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEEs), and RADIANT study data for vormatrigine in focal onset seizures and generalized epilepsy. Other 8-Ks outline pre-New Drug Application (NDA) meetings with the U.S. Food and Drug Administration (FDA), alignment on registrational pathways for elsunersen in early-onset SCN2A-DEE, and details of underwritten public offerings and at-the-market equity programs.
Investors can also use this page to monitor filings related to Praxis’ common stock listing on The Nasdaq Global Select Market under the symbol PRAX, shareholder meeting results, and executive compensation or governance matters disclosed in proxy-related documents. As Praxis advances ulixacaltamide, vormatrigine, relutrigine and elsunersen, its periodic and current reports are expected to discuss clinical progress, regulatory designations, risk factors and use of proceeds from financings.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the significance of each PRAX filing. Real-time updates from EDGAR, combined with accessible explanations of complex disclosures, make this page a practical starting point for analyzing Praxis Precision Medicines’ regulatory and financial reporting history.
This amendment to a Schedule 13G reports that Janus Henderson Group plc and an affiliated fund hold material stakes in Praxis Precision Medicines common stock. The filing shows Janus Henderson Group plc beneficially owns 2,533,405 shares, representing 12.4% of the class, with shared voting and dispositive power over those shares. Janus Henderson Biotech Innovation Master Fund Ltd is reported to beneficially own 1,186,586 shares ( 5.8% ).
The filing identifies indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) as registered investment advisers and includes a certification that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control. A power of attorney authorizes certain compliance officers to file and amend reporting documents on behalf of Janus Henderson.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, report beneficial ownership of 1,974,585 shares of Praxis Precision Medicines common stock, representing 9.69% of the outstanding class. The shares are directly held by Adage Capital Partners, L.P. and the percentage is calculated using an aggregate of 20,368,982 shares outstanding as reported by the company.
The filing shows shared voting and shared dispositive power for the reporting persons and no sole voting or dispositive power. It also certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Reporting entities are organized in Delaware and the named individuals are U.S. citizens.
Perceptive Advisors LLC, its Perceptive Life Sciences Master Fund, Ltd. and founder Joseph Edelman have filed a Schedule 13G disclosing a passive stake in Praxis Precision Medicines (PRAX).
- Shares owned: 1,362,503 common shares.
- Ownership percentage: 6.69 % of the 20,368,982 shares outstanding as of 30 Apr 2025.
- Control rights: The Reporting Persons hold shared voting and dispositive power over all shares; they report zero sole voting/dispositive power, indicating no unilateral control.
- Date of event: 15 Jul 2025; filing signed 22 Jul 2025.
- Filer status: Perceptive Advisors is an investment adviser (IA); Edelman is a U.S. individual; Master Fund is Cayman-based.
The certification states the securities were not acquired to influence control, confirming a passive investment posture. Perceptive’s >5 % position may draw investor attention because the healthcare-focused fund is considered a sophisticated life-sciences investor.
Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing that director Dean J. Mitchell received a new stock option grant for 10,520 common shares on 26 June 2025. The option carries an exercise price of $44.04 and expires on 26 June 2035. Vesting occurs in twelve equal monthly installments over one year starting on the grant date. No common shares were bought or sold; this is purely an equity-based compensation award that increases Mr. Mitchell’s derivative holdings to 10,520 options, all held directly. The transaction is routine and designed to align director incentives with shareholder interests, with minimal immediate balance-sheet or ownership impact on PRAX.
Praxis Precision Medicines (PRAX) – Form 4 Insider Activity
Director William D. Young disclosed the grant of a stock option for 10,520 common shares on 26-Jun-2025 at an exercise price of $44.04. The option vests in twelve equal monthly installments over one year, beginning on the grant date, and expires on 26-Jun-2035. No open-market purchases or sales of common stock were reported. Following the transaction, Mr. Young beneficially owns 10,520 derivative securities linked to PRAX common shares. The filing was executed on 27-Jun-2025.
Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing that director Gregory Norden received an option grant on 26 Jun 2025.
- Derivative security issued: Non-qualified stock option covering 10,520 common shares with an exercise price of $44.04.
- Vesting schedule: Vests in twelve equal monthly instalments beginning 26 Jun 2025, fully vested after one year.
- Expiration: 26 Jun 2035 (10-year term).
- Ownership impact: Following the grant, Norden beneficially owns 10,520 derivative securities (stock options) directly; no non-derivative share movement is reported.
The filing represents a routine equity incentive award to a board member and does not indicate any open-market purchase or sale of PRAX shares.
Praxis Precision Medicines, Inc. (PRAX) — Form 4 insider filing
Director Jill DeSimone received a new option grant on 26 June 2025. The grant covers 10,520 shares of common stock at an exercise price of $44.04 and expires on 26 June 2035. Vesting is scheduled in twelve equal monthly installments over one year beginning on the grant date, aligning compensation with near-term company performance. After this transaction Ms. DeSimone holds 10,520 derivative securities directly. No common-stock transactions, sales, or additional option exercises were reported.
The filing represents a routine equity incentive for a non-employee director and does not change PRAX’s share count in a material way. The transaction code "A" confirms an acquisition of options rather than an open-market purchase, so immediate cash outlay or insider buy-signal implications are minimal.
FAQ
What is the current stock price of Praxis Precision Medicines (PRAX)?
What is the market cap of Praxis Precision Medicines (PRAX)?
